接受90Y微球动脉内放射栓塞治疗患者治疗前99mTc-大颗粒白蛋白SPECT/CT与治疗后PET/MR研究的定量比较
本研究比较了32例原发性或转移性肝肿瘤患者治疗前99mTc-MAA SPECT/CT与治疗后90Y PET/MRI获得的90Y剂量学差异,全肝平均剂量分别为43.0 ± 20.9 Gy和46.5 ± 22.7 Gy,平均差异3.4 ± 6.2 Gy,Spearman相关系数ρ=0.92,结论认为两种方法获得的剂量学值无显著差异。
要点
- 治疗前MAA SPECT/CT与治疗后90Y PET/MRI的全肝平均剂量无显著差异。
- 肝脏最大剂量在两种模态间存在实质性差异,但平均剂量差异≤24.0%。
- 剂量学差异主要归因于导管位置变化及用于计算的肝脏ROI不同。
核心结论
- 治疗前MAA SPECT/CT与治疗后90Y PET/MRI获得的剂量学值无显著差异,差异主要源于导管位置变化和肝脏ROI选取不同。
研究设计与样本
- 研究纳入32例原发性或转移性肝肿瘤患者,放射栓塞前行99mTc-MAA SPECT/CT扫描模拟90Y分布,放射栓塞后行PET/MRI成像,图像传输至统一平台计算90Y剂量学,采用Passing-Bablok回归散点图和Bland-Altman法分析差异。
诊断标准与关键数值
- 全肝平均剂量:MAA SPECT/CT为43.0 ± 20.9 Gy,PET/MRI为46.5 ± 22.7 Gy,平均差异3.4 ± 6.2 Gy;重复性系数12.1(均值的27.0%);Spearman秩相关系数ρ=0.92;平均肝脏剂量差异≤24.0%。
临床应用与阅片要点
- 作者指出,MAA与90Y PET/MRI剂量学计算差异的两个主要贡献因素可归因于导管定位变化以及用于计算的肝脏ROI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of our study was to compare yttrium -90 (90Y) dosimetry obtained from pre-therapy 99mTc-macroaggregated albumin (MAA) SPECT/CT versus post-therapy PET/MRI imaging among patients with primary or metastatic hepatic tumors.
MATERIALS AND METHODS: Prior to 90Y radioembolization (RE), 32 patients underwent a scan using MAA mimicking 90Y distribution. After RE with 90Y microspheres, the patients were imaged on a PET/MRI system. Reconstructed images were transferred to a common platform and used to calculate 90Y dosimetry. The Passing-Bablok regression scatter diagram and the Bland and Altman method were used to analyze the difference between dosimetry values.
RESULTS: For MAA and PET/MRI modalities, the mean liver doses for all 32 subjects were 43.0 ± 20.9 Gy and 46.5 ± 22.7 Gy, respectively, with a mean difference of 3.4 ± 6.2 Gy. The repeatibility coefficient was 12.1 (27.0% of the mean). The Spearman rank correlation coefficient was high (ρ = 0.92). Although, there was a substantial difference in the maximum doses to the liver between the modalities, the mean liver doses were relatively close, with a difference of 24.0% or less.
CONCLUSIONS: The two main contributors to the difference between dosimetry calculations using MAA versus 90Y PET/MRI can be attributed to the changes in catheter positioning as well as the liver ROIs used for the calculations. In spite of these differences, our results demonstrate that the dosimetry values obtained from pre-therapy MAA SPECT/CT scans and PET/MRI post-therapy 90Y studies were not significantly different.
引用
- Knešaurek K, Tuli A, Pasik SD, et al. Quantitative comparison of pre-therapy 99mTc-macroaggregated albumin SPECT/CT and post-therapy PET/MR studies of patients who have received intra-arterial radioembolization therapy with 90Y microspheres. Eur J Radiol. 2018. PMID: 30527312. doi:10.1016/j.ejrad.2018.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。